Why Is UnitedHealth (UNH) Down 7.2% Since Last Earnings Report?

UnitedHealth reported Q3 2025 adjusted EPS of $2.92 (beat $2.75 est.) but down 59.2% year‑over‑year, with revenues of $113.2 billion (+12% y/y) missing consensus by ~0.2%. Medical costs surged to $80 billion (from $66B), pushing the medical care ratio to 89.9% (up 470 bps) and cutting operating earnings to $4.3 billion (down 50% y/y); UnitedHealthcare and Optum revenue growth was +16% and +8% respectively. Membership was 50.1 million (slightly below estimates), cash/short‑term investments were $30.6 billion, long‑term debt $72.4 billion, and management now guides 2025 adjusted EPS at least $16.25 (up from prior $16) with revenues targeted near $445.5–$448.0 billion, highlighting margin pressure despite top‑line growth and prompting recent investor caution.

Analysis

Market structure: UnitedHealth’s Q3 print shows revenue growth but acute margin compression (MCR +470bps YOY to 89.9%) — winners short-term are PBM/retail players (Optum Rx volume leaders like CVS/Caremark) and self‑funded commercial carriers able to pass costs to employers; losers are vertically integrated insurer margins and hospitals facing payment renegotiations. Pricing power is under pressure because medical cost trend > pricing; expect continued rate push in employer renewals over the next 12–18 months, which compresses earnings unless pricing catches up by >300–400bps.

Risk assessment: Tail risks include a CMS policy reversal or deeper Medicare funding cuts, a large catastrophic claim wave, or major litigation against Optum — each could cut EPS by >10–20% relative to guidance. In the next 7–30 days, stock volatility should remain elevated around quarterly catalysts; over 1–4 quarters margins can normalize if MCR retreats below ~88% and operating cash flow stabilizes near prior $20bn levels. Hidden dependencies: UNH’s leverage to pharmacy rebate dynamics, Medicare funding and employer renewal cadence are second‑order drivers of cash flow volatility.

Trade implications: Tactical hedges (options) are preferred to directional size: buy protection 1–3 months around earnings and CMS rule windows; consider pair trades that short UNH and go long purer managed‑care/Medicare specialists (HUM) to isolate Optum noise. Sector rotation: trim diversified healthcare exposure and increase allocation to PBM/retail (CVS) and high‑quality MA specialists where pricing pass‑through is clearer.

Contrarian angle: Market is treating margin hit as structural when much is policy/timing‑driven — if MCR reverts 100–200bps and guidance moves >+$1.00 EPS, sentiment can swing quickly. Historical parallels (post‑policy shocks 2014–2016) show large caps recover within 2–4 quarters once reimbursement clarity returns. Risk: short UNH is asymmetric — buybacks, cash balance ($30.6bn) and scale can blunt downside quickly.

Key Decisions for Investors

• Buy a protective UNH put spread: purchase 3‑month UNH 10% OTM puts and sell 5% OTM puts sized to risk ~1% of portfolio as a hedge into the next 30–90 day earnings/CMS windows.
• Establish a 2% portfolio long in HUM (Humana) vs a 2% short in UNH as a dollar‑neutral pair trade for 3–6 months to exploit relative margin resilience in focused Medicare Advantage exposure.
• Add a 1–2% tactical long position in CVS to capture Optum Rx share/mix tailwinds; trim general healthcare beta by 2–3% to keep net exposure neutral over the next 6 months.
• Reduce direct long UNH exposure unless one of two thresholds is hit: (A) MCR improves to <88% on a trailing‑4Q basis, or (B) management raises 2026 EPS guide to >$17.00 — only then add to 2–3% position.
• If UNH 5‑year credit spread widens by >50bps vs. IG median, consider opportunistic purchase of UNH bonds or CDS protection (horizon 12–24 months) — buys then price in undue credit stress while equity volatility is high.